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Abstract
Introduction Deregulation of Polycomb member Bmi-1 is
involved in cell proliferation and human oncogenesis.
Modulation of Bmi-1 is found in several tumor tissues, including
primary breast carcinomas; however, analysis of Bmi-1 in
plasma of cancer patients has not been reported. This is the first
study that evaluates Bmi-1 in plasma by using a large series of
primary breast carcinomas to investigate the presence at
diagnosis of detectable Bmi-1 mRNA in plasma and possible
correlations between this event and a series of clinical-
pathological parameters of the tumors.
Methods Bmi-1 expression levels were quantified in plasma of
111 breast cancer patients and in 20 healthy controls by real-
time quantitative polymerase chain reaction.
Results Cancer patients with the presence of Bmi-1 mRNA in
plasma had higher levels of Bmi-1  expression than healthy
controls with Bmi-1 mRNA in plasma. The higher expression
levels of Bmi-1 correlated with well-established markers of poor
clinical outcome in breast cancer such as positive p53
immunostaining and negative progesterone receptors.
Moreover, we described for the first time a statistically
significant correlation between Bmi-1 expression in plasma of
breast cancer patients and disease-free and overall survival in
advanced stages.
Conclusion Our results suggest that levels of Bmi-1 expression
may be a surrogate marker of poor prognosis and may become
clinically useful as noninvasive diagnostic markers.
Introduction
Early detection of breast cancer can improve survival, and
molecular techniques designed to detect metastases or recur-
rent disease in preclinical or presymptomatic phases may con-
tribute to this strategy. Increased levels of circulating nucleic
acids (CNAs) in the plasma or serum of cancer patients have
been described [1]. In addition, patients with metastases have
higher CNA levels than patients with localized disease [2].
Genetic and epigenetic tumor-associated DNA alterations
have been found in plasma of patients with different types of
cancer [3-6], which is related to poor prognosis, disease-free
survival (DFS), and overall survival (OS) [7-10]. Furthermore,
tumor-associated mRNA in plasma is also found in several
types of cancer, such as melanoma and breast, colon, and
nasopharyngeal carcinomas [11-17]. We reported previously
that mRNA-based amplification methods offered higher spe-
cificity and sensitivity than DNA in plasma of breast cancer
patients [18]. Additionally, an association between tumor
mRNA in plasma and pathological parameters compatible with
more aggressive tumors was observed [13,15,16]. Therefore,
the presence of tumor RNA in plasma could lead to the devel-
opment of a noninvasive prognostic method and prognostic
tool that would be useful during patients' follow-up and treat-
ment monitoring.
Bmi-1 is the first functional mammalian Polycomb group (PcG)
proto-oncogene to be recognized. The PcG consists of sev-
eral proteins that form multiprotein complexes that regulate
gene activity at the chromatin level. They were initially identi-
fied as part of the memory system that ensures the faithful
transmission of cell identities throughout cell division [19].
Although PcG protein expression is tightly regulated in normal
CI = confidence interval; CNA = circulating nucleic acid; DFS = disease-free survival; hTERT = human telomerase reverse transcriptase; OS = overall 
survival; PcG = Polycomb group; PCR = polymerase chain reaction; RT-PCR = reverse transcription-polymerase chain reaction; UBC = ubiquitin C.Breast Cancer Research    Vol 9 No 4    Silva et al.
Page 2 of 9
(page number not for citation purposes)
cell proliferation and differentiation, it is often deregulated in
several types of human cancer [20]. Several PcG genes,
including Bmi-1, regulate the self-renewal of specific stem cell
types, suggesting a link between the maintenance of cell
homeostasis and carcinogenesis [21,22].
Bmi-1 was initially identified as an oncogene involved in the
development of mouse pre-B-cell lymphomas cooperating
with c-Myc. In mice and in vitro studies have indicated that
Bmi-1 protein regulates the INK4a/ARF locus, which encodes
the two tumor suppressors, p16INK4a and p19ARF (p14ARF
in humans), which act in pRb and p53 cell cycle control path-
ways, respectively. In the absence of Bmi-1, p16INK4a may be
upregulated, resulting in hypophosphorylated pRb and leading
cell cycle arrest, senescence, or apoptosis, depending on the
context. In contrast, deregulation of p16INK4a by Bmi-1
involves pRb hyperphosphorylation, which allows cell cycle
progression. p19ARF prevents the degradation of p53 by
sequestering the p53-inhibitor MDM2, thereby allowing p53-
mediated cell cycle arrest and apoptosis [23-25]. Further evi-
dence for the oncogenic role of Bmi-1 was its activation of
human telomerase reverse transcriptase (hTERT), which
extended the replicative life span and immortalized mammary
epithelial cells, suggesting a potential regulation of telomerase
activity by Bmi-1 in human breast carcinogenesis [26].
Despite the above-mentioned evidence supporting the repres-
sion of the INK4a/ARF failsafe mechanism or the activation of
hTERT by Bmi-1, these associations have not been observed
in human breast tumors [27].
Nevertheless, Bmi-1-altered expression has frequently been
described in human tumors, mainly in hematological malignan-
cies [28-33]. Disturbed Bmi-1 expression has also been
reported, and correlates with poor prognosis parameters, in
solid tumors such as lung cancers [34], medulloblastomas
[35], neuroblastomas [36], liver [37], breast [38], colon [39],
nasopharyngeal [40], and prostate [41] carcinomas.
Despite the above, no analysis of Bmi-1 in plasma of cancer
patients has been reported. We evaluated Bmi-1 mRNA in
plasma from 111 primary breast carcinomas to investigate the
presence at diagnosis of detectable Bmi-1 mRNA in plasma
and possible correlations between this event and the specific
pathological and clinical parameters of tumors. Moreover, we
described for the first time a statistically significant correlation
between Bmi-1 expression in plasma of breast cancer patients
and survival in advanced stages.
Materials and methods
Plasma samples and mRNA isolation
Informed consent was obtained from all participants after an
explanation of the nature of the study, as approved by the
research ethics board of our hospital. Between August 2001
and November 2003, blood samples (20 ml) were taken from
111 patients with primary breast carcinoma by venipuncture
before intervention on the day of surgery: the first several mil-
liliters were discarded to eliminate skin-plug contamination.
Blood samples from 20 healthy blood donors were also
obtained at the hematology unit of our hospital. Plasma was
prepared by centrifugation of peripheral blood at 2,500 rpm
for 25 minutes and divided into aliquots, which were snap-fro-
zen at -80°C until processing. mRNA was extracted from 1 ml
of plasma sample by Dynabeads mRNA DIRECT Kit (Dynal
Biotech ASA, Oslo, Norway). Plasma was incubated with 200
μl of Dynabeads Oligo (dT) for 10 minutes at room tempera-
ture. mRNA was eluted in 10 mM Tris-HCl.
Clinical-pathological parameters
The following parameters were obtained from the medical
records of the 111 patients: age, tumor size, tumor histology,
lymph node metastases, presence of steroid receptors (estro-
gen and progesterone), clinical stage, histological grade, pro-
liferation index, erbB2 expression, vascular invasion, p53
immunoassay status, and presence of metastases. The clinical
stage was assessed using the tumor-node-metastasis classifi-
cation. The steroid receptor content was determined by an
immunohistochemical procedure. The proliferation index was
calculated by the Ki-67 antigen (Immunotech, Westbrook, ME,
USA) in immunohistochemistry analyses. c-erbB2 expression
was evaluated by a monoclonal mouse antibody (CB11; Novo-
castra Laboratories Ltd., Newcastle, UK). Immunohistochem-
istry of p53 was analyzed with the cl 1801 mouse monoclonal
antibody (Oncogene Science, now part of Siemens AG,
Munich, Germany) on the basis of its ability to detect up to
89% of p53 point mutations [42].
Figure 1
Size and sequence of specific Bmi-1 expression Size and sequence of specific Bmi-1 expression. Lanes 1 to 3 show 
serial dilution of the tumor cDNA used to generate standard curve (1:5, 
1:25, and 1:125). Lanes 4 and 5 show Bmi-1 expression in the plasma 
of a breast cancer patient and in the plasma of a healthy control, 
respectively. bp, base pairs; WM, weight marker.Available online http://breast-cancer-research.com/content/9/4/R55
Page 3 of 9
(page number not for citation purposes)
Real-time polymerase chain reaction analysis
Bmi-1 expression levels were quantified in plasma of the 111
breast cancer patients and the 20 healthy controls by real-time
quantitative polymerase chain reaction (PCR). Bmi-1 mRNA
levels were standardized using ubiquitin C (UBC) as a refer-
ence housekeeping gene. The relative concentrations of the
target and the reference gene were calculated by interpolation
by means of a standard curve of each gene plotted from the
same serial dilution of cDNA from tumor tissue. For the synthe-
sis of first-strand cDNA, mRNA was reverse-transcribed using
the Gold RNA PCR Core Kit (PE Biosystems, Foster City, CA,
USA) in accordance with the manufacturer's instructions. Ran-
dom hexamers were used as primers for cDNA synthesis.
Although DNA does not bind to the beads, we designed spe-
cific intron-spanning primers for reverse transcription (RT)-
PCR to avoid possible contamination. The cases in which
housekeeping mRNA was not found were eliminated from the
study. RT-PCR was performed in a Light-Cycler apparatus
(Roche Diagnostics GmbH, Mannheim, Germany) using the
LightCycler-FastStart DNA MasterPLUS  SYBR Green I Kit
(Roche Diagnostics GmbH) according to the manufacturer's
instructions. Each reaction was performed in a final volume of
20 μl containing 2 μl of the cDNA product sample, 3 mM
MgCl2, 0.5 μM of each primer, and 1× reaction mix, including
FastStart DNA polymerase, reaction buffer, dNTPs, and SYBR
green. The primers and conditions used are described in Table
1. Thermal cycling for both genes was initiated with a denatur-
ation step of 95°C for 10 minutes, followed by 30 to 35 cycles
(denaturation at 94°C for 2 seconds, specific annealing tem-
perature 5 seconds, and elongation at 72°C for 5 seconds, in
which fluorescence was acquired). At the end of the PCR
cycles, melting curve analyses and electrophoresis of the
products on nondenaturing 8% polyacrylamide gels, together
with a molecular weight marker (DNA Molecular Weight
Marker V; Roche Diagnostics GmbH), were run to validate the
generation of the expected specific PCR product (144 base
pairs). The allelic band intensity on the gels was detected by
nonradioisotopic means using a commercially available silver
staining method. The bands were sequenced in an ABI Prism™
377 DNA sequencer apparatus (PE Applied Biosystems Fos-
ter City, CA, USA) (Figure 1).
Patient follow-up
Clinical follow-up after surgery and diagnosis was based on
periodic visits (every 3 months during the first year, every 6
months during the second year, and then yearly until relapse in
our medical oncology department, complemented by other
periodic controls in health centers of our hospital) and on clin-
ical, biochemical, and imaging techniques (chest x-ray, bone
scan, and other areas as clinically indicated). Ultrasonic study
was performed when liver function was impaired. OS and
DFS, defined as the period from time of diagnosis until death
and the interval between diagnosis and first recurrence,
respectively, were the study endpoints. Follow-up data were
obtained from 98 patients.
Data analysis
Bmi-1  expression data were not normally distributed (Kol-
mogorov-Smirnov test). Due to the non-normal distribution of
the expression data, both healthy and patient samples were
contrasted with Bmi-1  expression data in plasma by the
Kruskal-Wallis test. When Bmi-1  expression was not
detected, one of 10 equal parts of the minimum value detected
in the series was assigned. Statistical analysis was performed
using the SPSS package, version 11.0 (SPSS Inc., Chicago,
IL, USA).
Results
Bmi-1 mRNA expression levels
mRNA of housekeeping gene UBC was detected by real-time
PCR in the plasma of all samples. Bmi-1 mRNA in plasma was
identified in 48 of the 111 breast cancer samples (43.2%) and
in 11 of the 20 healthy controls (55%). To validate the Bmi-1
expression results, we analyzed the mRNA Bmi-1 expression
in a series of 10 mRNA samples from plasma of tumor patients
included in the study with a new set of optimized primers.
When we analyzed the expression with the original primers in
these 10 samples, three showed absence of Bmi-1, two
showed low levels, two showed medium levels, and the other
three showed high levels of mRNA Bmi-1. The mRNA Bmi-1
expression analysis of these samples with the new set of prim-
ers showed precisely the same results as those obtained with
the current set. The primers and conditions used are
Table 1
Primer sequences and temperature conditions for real-time quantification analysis
Primer Sequence Annealing temperature (°C)
BmiQ-F GCTTCAAGATGGCCGCTTG 65
BmiQ-R TTCTCGTTGTTCGATGCATTTC
BmiQ-F2 CATTGTCTTTTCCGCCCGC 63
BmiQ-R2 CAAAGCACACACATCAGGTGGG
UbcQ-F ATTTGGGTCGCGGTTCTTG 59
UbcQ-R TGCCTTGACATTCTCGATGGTBreast Cancer Research    Vol 9 No 4    Silva et al.
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described in Table 1. The Kruskal-Wallis test showed that
cancer patients with the presence of Bmi-1 mRNA in plasma
showed a tendency to have higher levels of Bmi-1 expression
than healthy controls with Bmi-1 mRNA in plasma (p = 0.07)
(Figure 2). Interestingly, when we compared Bmi-1 mRNA lev-
els (taking into consideration only the positive cases in both
populations), the Kruskal-Wallis test showed a p value with
statistical significance (p = 0.019) (Table 2).
Correlation between Bmi-1 mRNA expression and 
clinical-pathological parameters
When we correlated gene expression with clinical-pathologi-
cal features of the tumors, some analyzed parameters in pri-
mary breast cancer samples showed significant associations
with Bmi-1 mRNA expression levels in plasma. Thus, higher
expression levels of Bmi-1 correlated with positive p53 immu-
nostaining and with negative progesterone receptors (Table
3).
Correlation between Bmi-1 mRNA expression and 
disease-free and overall survival
A total of 96 patients with survival data were followed up with
for 54 months, and during this period 20 (20.4%) recurrences
were observed. Kaplan-Meier analysis of our series showed
that in the first year of follow-up, DFS was 93.5% (95% confi-
dence interval [CI], 87.62% to 99.38%); in the second, DFS
was 85.6% (95% CI, 77.76% to 93.44%); in the third, it was
81.2% (95% CI, 73.36% to 89.04%); and in the fourth year, it
was 68% (95% CI, 50.36% to 85.64%).
Patients were divided into two groups for the detection of
Bmi-1 mRNA in plasma. Thus, the plasma of breast cancer
patients had the absence or presence of Bmi-1 expression.
When DFS was analyzed by Kaplan-Meier in relation to Bmi-1
expression, no statistically significant values were observed (p
= 0.41). Similarly, OS was not statistically significant for
expression of mRNA levels of Bmi-1 in plasma (p = 0.13). In
addition, we included other clinical-pathological parameters in
the analysis to make the study more comprehensive. Interest-
ingly, when DFS was analyzed in relation to the clinical stage
of the tumors concomitantly with the presence or absence of
Bmi-1, a trend to statistically significant association between
the presence of Bmi-1 and more advanced stages of the dis-
ease was observed (p = 0.08). Similarly, when we analyzed
OS, including the clinical stage of the tumors, a statistically
significant effect of Bmi-1 presence in plasma was observed
(p = 0.0032). Differences in DFS and OS when we compared
the absence/presence of Bmi-1 in clinical stages I+II versus
stage III are described in Table 4 and Figure 3.
Figure 2
Differences between Bmi-1 expression levels in healthy controls and tumor samples Differences between Bmi-1 expression levels in healthy controls and tumor samples. UBC, ubiquitin C.
Table 2
Kruskal-Wallis analysis of Bmi-1 mRNA in plasma from positive healthy controls and breast cancer patients
Population Number Minimum Maximum Median P value
Healthy controls 11 0.055 0.387 0.254 0.019
Breast cancer patients 48 0.041 9.054 0.411Available online http://breast-cancer-research.com/content/9/4/R55
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Table 3
Associations between Bmi-1 expression in plasma and clinical-pathological characteristics
Parameter Number Mean rank P value
Age
More than 50 years 66 57.20 NS
Less than 50 years 42 50.26
Histology
Invasive ductal carcinoma 79 52.05 NS
Invasive lobular carcinoma 12 54.08
Other 10 39.00
Vascular invasion
Yes 16 55.69 NS
No 85 50.12
Tumor size
More than 2 cm 54 51.41 NS
Less than 2 cm 44 47.16
Lymph node metastases
Yes 45 47.80 NS
No 52 50.04
Histological grade
I 18 41.94 NS
II 30 37.67
III 33 43.52
Estrogen receptor
Positive 74 47.15 NS
Negative 24 56.75
Progesterone receptor
Positive 73 46.10 0.027
Negative 25 59.44
c-erbB2
Positive 27 34.63 NS
Negative 37 30.95
p53
Positive 26 56.98 0.011
Negative 66 42.37
Ki-67
Positive 67 48.74 NS
Negative 27 44.43
Metastases
Yes 3 58.17 NS
No 95 49.23
Stage
I 26 54.50
II 54 46.59 NS
III 15 49.67
IV 3 57.67
NS, not significant.Breast Cancer Research    Vol 9 No 4    Silva et al.
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Discussion
The PcG protein Bmi-1 is a transcriptional repressor that has
been involved in axial patterning, hematopoiesis, regulation of
cell proliferation, senescence, and regulation of stem cell self-
renewal. Bmi-1 expression is often deregulated in several
types of human cancer, including hematological and solid
tumors, which correlate with poor prognosis parameters.
Moreover, Bmi-1 has recently been shown to be a useful
molecular marker for predicting occurrence and prognosis in
high-susceptibility cancer syndromes such as myelodysplastic
syndrome [43]. The main line of evidence involving Bmi-1 in
tumorigenesis is the repression of INK4a/ARF suppressor pro-
teins, deregulating both pRb and p53 cell cycle control path-
ways, facilitating cell proliferation, and desensitizing cells to
apoptosis. However, the effect of Bmi-1 overexpression on the
inactivation of the INK4a/ARF  transcripts in human breast
cancer is unclear, as we reported previously [27].
Although all studies analyzing the deregulated expression of
Bmi-1 have been conducted in primary tumors, no data on
Bmi-1 in plasma of cancer patients have been reported. Thus,
we attempted to detect Bmi-1 mRNA in plasma from a large
series of 111 patients with primary breast carcinomas to
assess its possible value as a prognostic marker and its appli-
cability as a noninvasive tool for prognosis.
Bmi-1 mRNA in plasma detected by real-time PCR was iden-
tified in 43.2% of the breast cancer samples and in 55% of the
healthy controls. The presence of free CNAs has been
observed in healthy controls [1,2], and Bmi-1 expression has
been reported in nontumor tissue thought to be at lower levels
than tumor tissues [37,38]. Thus, it was not surprising that we
found Bmi-1 mRNA in plasma of healthy controls. Neverthe-
less, although the frequency of detection was slightly higher in
the healthy population than in cancer patients, the values of
mean rank and statistical significance obtained in the Kruskal-
Wallis test showed that Bmi-1 mRNA expression levels were
higher in plasma from breast carcinoma patients than Bmi-1
mRNA expression levels in plasma from healthy controls. Fur-
thermore, high expression levels of Bmi-1 correlated with sev-
eral clinical-pathological features of the tumors. Positive
nuclear immunostaining of p53 (suggestive of p53 mutation)
and negative progesterone receptor immunohistochemistry
are well-established markers of poor clinical outcome in breast
Table 4
Analysis of the association between plasma Bmi-1 expression levels and disease-free or overall survival in breast cancer patients 
regarding pathological stages
Disease-free survival Bmi-1 absence Bmi-1 presence Bmi-1 absence Bmi-1 presence
Stages I+II Stages I+II Stage III Stage III
N = 43 N = 36 N = 8 N = 7
Cumulative survival
First year 95.2% (89.3%–100%) 100% 85.7% (60.2%–100%) 71.4% (45.9%–96.8%)
Second year 87.9% (78.1%–97.7%) 96.8% (90.9%–100%) 85.7% (60.2%–100%) 42.8% (5.5%–80.1%)
Third year 84.9% (73.1%–96.6%) 91.4% (79.6%–100%) 85.7% (60.2%–100%) 28.5% (0%–61.8%)
Fourth year 80.2% (66.5%–93.9%) 91.4% (79.6%–100%) 57.1% (11.1%–100%) 28.5% (0%–61.8%)
56 months 80.2% (66.5%–93.9%) 61.1% (12.1%–100%) 57.1% (11.1%–100%) 28.5% (0%–61.8%)
Significance NS 0.08
Overall survival Bmi-1 absence Bmi-1 presence Bmi-1 absence Bmi-1 presence
Stages I+II Stages I+II Stages III+IV Stages III+IV
N = 43 N = 36 N = 8 N = 9
Cumulative survival
First year 97.5% (93.6%–100%) 100% 100% 88.8% (69.2%–100%)
Second year 95.1% (89.2%–100%) 100% 100% 55.5% (25.2%–86.8%)
Third year 89.9% (80.1%–99.7%) 100% 100% 22.2% (0%–49.6%)
Fourth year 89.9% (80.1%–99.7%) 92.3% (78.6%–100%) 100% 22.2% (0%–49.6%)
56 months 0% 92.3% (78.6%–100%) 0% 22.2% (0%–49.6%)
Significance NS 0.0032
Values in parentheses are 95% confidence intervals. NS, not significant.Available online http://breast-cancer-research.com/content/9/4/R55
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cancer. Both alteration markers were statistically associated
with the higher expression levels of Bmi-1 in plasma. We pre-
viously reported a correlation between expression of Bmi-1
and p53 and steroid receptor immunostaining in primary
breast tumors [27]. Interestingly, in this previous study, we
found that Bmi-1 overexpression was associated with nega-
tive p53 and positive progesterone receptor staining, which
clearly showed differences between cancer cells in primary
tumor and CNA-free cells in plasma. Our results showed that
increased Bmi-1 expression measured in CNA-free cells in
plasma was associated with more malignant conditions in the
primary location of tumor, such as altered p53 cell cycle-regu-
lating pathway and a more undifferentiated stage.
Initially, our data show no correlation between the presence of
Bmi-1 mRNA detected in plasma of breast cancer patients
and shorter DFS or OS evaluated by Kaplan-Meier analysis.
Nevertheless, we observed a statistically significant associa-
tion between the presence of Bmi-1 in plasma and survival
when we included the clinical stage in the analysis. In fact, this
stratified analysis showed a trend to statistical significance
between lower DFS in those patients with the presence of
Bmi-1 in plasma in more advanced stages of the disease and
the remainder. More statistically significant effects of the pres-
ence of Bmi-1 in plasma in advanced stages were observed
when OS was analyzed. The finding that the presence of Bmi-
1 in plasma in advanced clinical stages predicted OS with
Figure 3
Kaplan-Meier survival curves analyzed by stages for the influence of Bmi-1 presence in plasma on disease-free and overall survival Kaplan-Meier survival curves analyzed by stages for the influence of Bmi-1 presence in plasma on disease-free and overall survival.Breast Cancer Research    Vol 9 No 4    Silva et al.
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more statistical efficiency than DFS suggests that Bmi-1 may
be involved in the aggressiveness of the disease rather than in
the time of relapse.
In conclusion, in the present study, we examined the mRNA
levels of Bmi-1 in plasma in a large series of primary breast
carcinomas. To our knowledge, this is the first study on the
expression of oncogene Bmi-1 in plasma of cancer patients.
We found associations between high levels of Bmi-1 and sev-
eral clinical-pathological parameters for poor prognosis, such
as positive p53 and negative progesterone receptor staining.
Moreover, we associated the mRNA presence of this PcG
gene in plasma with worse survival at a more advanced clinical
stage, indicating that this may affect the outcome of the dis-
ease. Our results from the correlative analysis suggested that
the presence of Bmi-1 mRNA in plasma of patients with breast
tumors may be a possible prognostic marker, which can be
obtained by a noninvasive method.
Conclusion
Early detection of breast cancer is critical for improving sur-
vival of patients. Techniques designed to detect metastases or
recurrent disease in preclinical states may contribute to this
purpose. We evaluated for the first time the oncogene Bmi-1
in plasma in a large series of primary breast carcinomas to
investigate the presence at diagnosis of detectable Bmi-1
mRNA in plasma and its possible correlations with clinical-
pathological parameters of the tumors and survival of patients.
Our results suggest that levels of Bmi-1 expression may be a
surrogate marker of poor prognosis and may become clinically
useful as noninvasive diagnostic markers.
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